🍄Course: How To Grow Mushrooms is open!
Let's Shroom.
How to Become a Psychedelic Therapist | Recording

How to Become a Psychedelic Therapist | Recording

DoubleBlind Mag:
Issue 5

DB 102: How To Grow
Mushrooms - Bigger
& Better Yields

Regular price
$15.00
Sale price
$15.00
Unit price
per 

Join DoubleBlind and Dr. Ingmar Gorman, co-founder of Fluence, to learn what becoming a psychedelic therapist entails. Get instant access to the previously recorded Webinar + extra resources.

It’s now widely accepted among professionals in the psychedelic community that psychedelics will be legal, in therapeutic contexts, in the next decade. That means that we’ll need an entire infrastructure to support that, and one of the key components will be therapists who are competent in helping people prepare for, navigate, and process their psychedelic experiences.

In recent years, a number of programs and schools have emerged in preparation for the forthcoming psychedelic medical paradigm, from weekend-long trainings to degrees. Where does a person who wants to help others with their psychedelic experiences begin? If you’re a licensed counselor of some kind already, what are the best next steps for becoming trained in psychedelic integration therapy? What do trainings like this entail? What makes for a good psychedelic therapist anyway? And if you’re not a licensed counselor—say a journey facilitator without a degree in counseling or just a person who wants to get into the psychedelic field—what are your options? We’ll explore all this and more in our 90-minute webinar with Dr. Ingmar Gorman. There will also be time for questions from our community at the end.

About Dr. Ingmar Gorman

Dr. Ingmar Gorman is a co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. As a psychologist, he shares his expertise in empirically supported psychedelic treatments with his clients and trainees alike. Dr. Gorman received his clinical training in New York City at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University. He simultaneously served as site co-principal investigator on an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and is currently a study therapist on the same study, as well as another FDA approved clinical trial of psilocybin for treatment resistant depression. Dr. Gorman has published on the topics of classic psychedelics, ketamine, MDMA, and Psychedelic Harm Reduction and Integration.